Das Produkt wurde korrekt in den Warenkorb gelegt.

discount label
H-ASMTNMELM-OH
3D-Ansicht

Biosynth logo

H-ASMTNMELM-OH

Ref. 3D-PP44308

1mg
217,00 €
10mg
253,00 €
100mg
455,00 €
Voraussichtliche Lieferung in Vereinigte Staaten, am Freitag 27. Dezember 2024

Produktinformation

Name:
H-ASMTNMELM-OH
Synonyme:
  • NH2-Ala-Ser-Met-Thr-Asn-Met-Glu-Leu-Met-OH
Beschreibung:

Peptide H-ASMTNMELM-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-ASMTNMELM-OH include the following: Myeloid Cell-Triggered in Situ Cell Engineering for Robust Vaccine-Based Cancer Treatment WH Li, JY Su, BD Zhang, L Zhao, SH Zhuo - Advanced , 2024 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/adma.202308155 Effective neoantigen vaccination correlates with generation of antigen-specific CX3CR1+CD8+ T cells mediated by CD40 and CD80/86 signaling in cDC1s T Yamauchi , T Hoki , T Oba , X Cao, F Ito - bioRxiv, 2020 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2020.06.15.151787.abstract CD40 and CD80/86 signaling in cDC1s mediate effective neoantigen vaccination and generation of antigen-specific CX3CR1+ CD8+ T cells T Yamauchi , T Hoki , T Oba , R Kajihara - Cancer Immunology , 2022 - Springerhttps://link.springer.com/article/10.1007/s00262-021-02969-6 Responsive multivesicular polymeric nanovaccines that codeliver STING agonists and neoantigens for combination tumor immunotherapy T Su, F Cheng, J Qi, Y Zhang, S Zhou , L Mei - Advanced , 2022 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/advs.202201895 Designer vaccine nanodiscs for personalized cancer immunotherapy R Kuai , LJ Ochyl , KS Bahjat , A Schwendeman - Nature materials, 2017 - nature.comhttps://www.nature.com/articles/nmat4822 A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer Q Ni , F Zhang , Y Liu , Z Wang , G Yu , B Liang, G Niu - Science , 2020 - science.orghttps://www.science.org/doi/abs/10.1126/sciadv.aaw6071 Non-covalent glycosylated gold nanoparticles/peptides nanovaccine as potential cancer vaccines L Zeng, Z Liao, W Li, Q Yuan , P Wu, Z Gu , Z Liu - Chinese Chemical , 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1001841719306199 Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy L Beziaud, L Boullerot, T Tran, L Mansi - Journal of Cancer, 2018 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.31842 Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8+ T cells KS Park , J Nam , S Son , JJ Moon - Biomaterials, 2021 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0142961221002003 Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy J Niemann, N Woller, J Brooks - Nature , 2019 - nature.comhttps://www.nature.com/articles/s41467-019-11137-5 A Universal Cyclodextrin-Based Nanovaccine Platform Delivers Epitope Peptides for Enhanced Antitumor Immunity J Mao, Z Jin, X Rui, L Li, C Hou, X Leng - Advanced , 2023 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/adhm.202301099 Discovering tumor-reactive T-cell receptors through single-cell sequencing of tumor-infiltrating lymphocytes E Gottschalk, BA Aksoy , P Aksoy , M Swiderska-syn - bioRxiv, 2021 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2021.11.30.470597.abstract Co-Delivery of Peptide Neoantigens and Stimulator of Interferon Genes (STING) Agonists Enhances Response to Cancer Vaccines D Shae , JJ Baljon , M Wehbe , PP Christov, KW Becker - academia.eduhttps://www.academia.edu/download/89775167/pdf.pdf Co-delivery of peptide neoantigens and stimulator of interferon genes agonists enhances response to cancer vaccines D Shae , JJ Baljon , M Wehbe , PP Christov, KW Becker - ACS , 2020 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acsnano.0c02765 Positron emission tomography-guided photodynamic therapy with biodegradable mesoporous silica nanoparticles for personalized cancer immunotherapy C Xu , J Nam , H Hong , Y Xu, JJ Moon - ACS nano, 2019 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acsnano.9b06691 Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer C van den Ende, D Ruano, K Franken, GMC Janssen - 2019 - academia.eduhttps://www.academia.edu/download/73699300/2162402X.2019.pdf Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer BJ Hos, MGM Camps, J Bulk , E Tondini - , 2020 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2019.1673125 Bulk,. an den B Hos, MGM Camps - , E., Ende, TC , 2020 - scholarlypublications https://scholarlypublications.universiteitleiden.nl/access/item%3A3221192/download Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells AR Sanchez-Paulete , FJ Cueto , M Martaca­nez-Lopez - Cancer discovery, 2016 - AACRhttps://aacrjournals.org/cancerdiscovery/article-abstract/6/1/71/5336

Hinweis:
Unsere Produkte sind nur für Laborzwecke. Für jede andere Verwendung, bitte melden sie sich bei uns.
Marke:
Biosynth
Langzeitlagerung:
Hinweise:

Chemische Eigenschaften

MDL:
Schmelzpunkt:
Siedepunkt:
Flammpunkt:
Dichte:
Konzentration:
EINECS:
Merck:
HS-Code:

Gefahrenhinweise

UN-Nummer:
EQ:
Klasse:
H-Sätze:
P-Sätze:
Flugverbot:
Gefahrenhinweis:
Verpackungsgruppe:
LQ:

Technische Anfrage zu: 3D-PP44308 H-ASMTNMELM-OH

Bitte verwenden Sie stattdessen den Warenkorb, um ein Angebot oder eine Bestellung anzufordern

Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.

* Obligatorische felder
Willkommen bei CymitQuimica!Wir verwenden Cookies, um Ihren Besuch zu verbessern. Wir schließen Werbung nicht ein.

Bitte beachten Sie unsere Cookie-Richtlinie  für weitere Details oder passen Sie Ihre Einstellungen unter “Konfigurieren” an.